美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

219.95

-4.7800-2.13%

盤後：219.950.00000.00%18:20 EDT

成交量：26.28萬

成交額：5,823.34萬

市值：237.67億

市盈率：-59.39

高：225.91

開：223.20

低：218.31

收：224.73

資料載入中...

總覽公司新聞資訊公告

百濟神州：澤布替尼新劑型預計今年下半年在歐美獲批

百濟神州5月7日成交額為1.58億美元

兩大千億營收巨頭領跑！雲南白藥首破400億，百濟神州、恆瑞大漲，人福、片仔癀……創新高

【券商聚焦】海通國際維持百濟神州(06160)“優於大市”評級指其業績整體符合預期

百濟神州：Q1 收入增 49% 扭虧為盈

金十數據整理：每日港股市場要聞速遞（5月8日週四）

百濟神州一季度虧損收窄，昊海生科實控人被立案，“減肥神藥”司美格魯肽Q1爆賣近80億美元，德展健康涉合同糾紛訴訟

百濟首次實現季度營業利潤扭虧，澤布替尼銷售額近57億元

百濟神州一季度虧損大幅收窄國內BTK抑制劑銷售加速、PD-1銷售減速

每日经济新闻

百濟神州一季度產品收入近80億元：跨越“創新鴻溝”，全球化突圍成盈利勝負手

21世纪经济报道

年內股價漲幅超三成的百濟神州，一季度營業利潤扭虧為盈

異動解讀 | 百濟神州一季度業績改善但盤前大跌5.25%，市場反應存疑

異動解讀 | 百濟神州股價盤前大跌5.25%，Q1財報虧損遠超預期

百濟神州第一季度淨利虧損9450.3萬元，同比大幅減虧

百濟神州(688235.SH)一季度營業總收入80.48億元，同比增長50.2%

百濟神州首次實現季度GAAP盈利一季度澤布替尼全球銷售額超50億元

百濟神州（06160）2025Q1強勁增長首次實現季度GAAP盈利

A股公告精選 | 百濟神州(688235.SH)第一季度營業利潤、利潤總額由虧轉盈

智通财经网

百濟神州：第一季度淨虧損9450.3萬元

每日经济新闻

百濟神州Q1營收增長50.2%至80.48億元，百悅澤®全球銷售額總計56.92億

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":219.95,"timestamp":1747252800000,"preClose":224.73,"halted":0,"volume":262785,"hourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"delay":0,"floatShares":78938275,"shares":108055817,"eps":-3.70325,"marketStatus":"已收盤","change":-4.78,"latestTime":"05-14 16:00:00 EDT","open":223.2,"high":225.91,"low":218.31,"amount":58233410.90145,"amplitude":0.033818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1747296000000},"marketStatusCode":5,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":224.73,"preHourTrading":{"tag":"盘前","latestPrice":224.68,"preClose":224.73,"latestTime":"09:29 EDT","volume":19,"amount":4262.519850000001,"timestamp":1747229360067},"postHourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"volumeRatio":0.523813,"impliedVol":0.404,"impliedVolPercentile":0.1758},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":78938275,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.523813,"shares":108055817,"dividePrice":0,"high":225.91,"amplitude":0.033818,"preClose":224.73,"low":218.31,"week52Low":141.31,"pbRate":"6.79","psRate":"5.69","week52High":287.88,"institutionHeld":0,"latestPrice":219.95,"eps":-3.70325,"divideRate":0,"volume":262785,"delay":0,"ttmEps":-3.70325,"open":223.2,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":232.25,"twentyDayClose":238.84,"sixtyDayClose":238.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533917313","title":"百濟神州：澤布替尼新劑型預計今年下半年在歐美獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2533917313","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533917313?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 10:35","pubTimestamp":1746671753,"startTime":"0","endTime":"0","summary":"目前泽布替尼获批的剂型为胶囊。百济神州已计划对R/R MCL适应症的II期临床试验进行数据读出并有望针对该项适应症在2025年下半年递交全球加速上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508105036a47617c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","BK1588","06160","ONC","BK1161","BK1583","LU0307460666.USD","688235"],"gpt_icon":0},{"id":"2533146059","title":"百濟神州5月7日成交額為1.58億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533146059","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533146059?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 10:21","pubTimestamp":1746670879,"startTime":"0","endTime":"0","summary":"美东时间2025年5月7日，百济神州成交额为1.58亿美元，成交额较昨日减少33.37%，当日成交量为67.72万股。百济神州于2025年5月7日跌3.93%，报232.25美元，该股过去5个交易日跌10.61%，年初至今涨25.74%，过去60日涨5.73%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508102121a6d70751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508102121a6d70751&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2533914871","title":"兩大千億營收巨頭領跑！雲南白藥首破400億，百濟神州、恆瑞大漲，人福、片仔癀……創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2533914871","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533914871?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 10:08","pubTimestamp":1746670080,"startTime":"0","endTime":"0","summary":"从营收增速来看，百济神州、新和成、恒瑞医药、华润三九等5家均有双位数增长；智飞生物跌幅最大，超过50%。上海医药、九州通两家千亿营收龙头继续领跑，重药控股、南京医药、国药股份均超过500亿元。创新高，云南白药首破400亿此外，人福医药、恒瑞医药、科伦药业、片仔癀等超20家创新高。其中，国药股份首次突破500亿元，云南白药首次突破400亿元，百济神州、新和成和鹭燕医药首次突破200亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050810152094efe52a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050810152094efe52a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600436","688235","06160","000538","600276","ONC"],"gpt_icon":0},{"id":"2533198039","title":"【券商聚焦】海通國際維持百濟神州(06160)“優於大市”評級 指其業績整體符合預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2533198039","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533198039?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 09:55","pubTimestamp":1746669314,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际发研指，1Q25百济神州 实现收入11.2亿美元，其中产品收入11.1亿美元。管理层维持全年49-53亿美元收入指引不变。该行认为百济神州的业绩整体符合预期。该行指，1Q25公司产品收入同比增长48.4%至11.1亿美元，主要得益于泽布替尼的海外销售增长。分产品来看：泽布替尼实现收入7.9亿美元。截至1Q25公司在手现金及现金等价物25.2亿美元。基于WACC9%，永续增长率4.0%（均不变），对应目标价182.35元港币，维持“优于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1958309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2533943780","title":"百濟神州：Q1 收入增 49% 扭虧為盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533943780","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533943780?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 09:36","pubTimestamp":1746668205,"startTime":"0","endTime":"0","summary":"百济神州第一季度总收入 11.17 亿美元，同比增加 49%；经调整净利润 1.36 亿美元，同比扭亏，增长主因是百悦泽在美欧销售额增长。宜明昂科根据授权及合作协议已自 AxionBio 收取 500 万美元的第二笔近期付款，预计未来将收取不超 3000 万美元的余下潜在近期付款。香港宽频中国移动香港完成收购公司 15.46%股份。安踏体育15 亿欧元零息有担保可换股债券换股价调整为每股 102.62 港元。正荣地产前 4 个月累计合约销售额约 14.96 亿元，同比减少 33.06。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050811424794effe20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050811424794effe20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2533918950","title":"金十數據整理：每日港股市場要聞速遞（5月8日 週四）","url":"https://stock-news.laohu8.com/highlight/detail?id=2533918950","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533918950?lang=zh_tw&edition=fundamental","pubTime":"2025-05-08 09:13","pubTimestamp":1746666783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1226287529.USD","LU1497734951.SGD","BK1119","IE00BZ08YR35.GBP","LU0149721374.USD","LU0320764599.SGD","02020","LU0516422952.EUR","YANG","MEURmain","600735","BK1578","CHL","LU0605514214.HKD","ANPDY","IE00B031J352.USD","600941","06158","LU0251143458.SGD","BK1539","LU1497733557.USD","80883","00168","LU2039709279.SGD","03301","BK1152","01541","GELYY","LU0164880469.USD","LU1064130708.USD","LU1226287875.USD","EUO","BK1227","07226","EURmain","FXE","LU0708995583.HKD","82020","688235","00175","80175","ZK","EVS.SI","06160","HSCEI","BK1610","ONC","01310","00941","HSTECH"],"gpt_icon":0},{"id":"2533960884","title":"百濟神州一季度虧損收窄，昊海生科實控人被立案，“減肥神藥”司美格魯肽Q1爆賣近80億美元，德展健康涉合同糾紛訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2533960884","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533960884?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 23:45","pubTimestamp":1746632754,"startTime":"0","endTime":"0","summary":"因公司原控股股东美林控股集团有限公司的关联方天宝嘉麟国际贸易有限公司与北京华新之间合同纠纷，北京华新向北京三中院提起诉讼。北京三中院裁定驳回北京华新的起诉。北京华新向北京高院提起上诉，请求依法撤销北京三中院的民事裁定书，并指令北京三中院对本案进行实体审理并作出公正判决及本案全部诉讼费用由被上诉人承担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508051033a475cdc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508051033a475cdc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK4139"],"gpt_icon":0},{"id":"2533303749","title":"百濟首次實現季度營業利潤扭虧，澤布替尼銷售額近57億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533303749","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533303749?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 22:50","pubTimestamp":1746629428,"startTime":"0","endTime":"0","summary":"2025年第一季度，百济神州实现营收80.48亿元，同比增长50.2%，其中产品收入79.85亿元，同比增长49.9%。根据A股业绩快报，百济神州实现营业利润、利润总额由亏损转为盈利，分别为1.51亿元、1.5亿元。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。今年第一季度，泽布替尼全球销售额为56.92亿元，同比增长63.7%。百济神州称，泽布替尼本季度首次位居美国BTK抑制剂领域市场份额首位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507225321a475803f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507225321a475803f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","688235"],"gpt_icon":0},{"id":"2533932462","title":"百濟神州一季度虧損大幅收窄 國內BTK抑制劑銷售加速、PD-1銷售減速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932462","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533932462?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 22:41","pubTimestamp":1746628873,"startTime":"0","endTime":"0","summary":"作为国内创新药龙头企业，百济神州目前有3款主要自研产品，分别为BTK抑制剂泽布替尼、PD-1单抗替雷利珠单抗和PARP抑制剂帕米帕利。对于一季度的产品收入增长，公司归因于百悦泽、百泽安及安进授权产品的销售增长。具体来说，今年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%。而在竞争更为激烈的国内PD-1单抗市场中，百泽安实现销售额12.45亿元，同比增长19.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","PD","06160","BK4139","BK4023","ONC","LU1169590202.USD","688235"],"gpt_icon":0},{"id":"2533939776","title":"百濟神州一季度產品收入近80億元：跨越“創新鴻溝”，全球化突圍成盈利勝負手","url":"https://stock-news.laohu8.com/highlight/detail?id=2533939776","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533939776?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 21:53","pubTimestamp":1746625980,"startTime":"0","endTime":"0","summary":"具体来看，业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。基于此，百济神州预计2025年全年营业收入将介于人民币 352亿元至 381 亿元之间。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。在海外市场，百济神州在2024年10月初高调宣布，其PD-1抗癌药物替雷利珠单抗在获得FDA批准六个多月后，终于在美国正式上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","688235","06160"],"gpt_icon":0},{"id":"2533936482","title":"年內股價漲幅超三成的百濟神州，一季度營業利潤扭虧為盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533936482","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533936482?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 21:40","pubTimestamp":1746625243,"startTime":"0","endTime":"0","summary":"今年以来，百济神州（ONC.NS、06160.HK、688235.SH）美股、港股、A股三地的股价累计涨幅均超过30%。5月7日晚间，百济神州公布的2025年第一季度美股业绩报告及A股业绩快报显示，公司业绩有继续向好趋势。百济神州A股业绩快报显示，2025年第一季度，公司实现营业利润、利润总额由亏损转为盈利，均实现盈利1.5亿元左右。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398404544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398404544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","BK1500","LU0307460666.USD","06160","LU0588546209.SGD","BK1583","BK4139","ONC","BK1161","BK1588","LU1969619763.USD"],"gpt_icon":0},{"id":"1155121510","title":"異動解讀 | 百濟神州一季度業績改善但盤前大跌5.25%，市場反應存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1155121510","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155121510?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:49","pubTimestamp":1746622160,"startTime":"0","endTime":"0","summary":"尽管百济神州发布的2025年第一季度财报显示业绩明显改善，但该公司股价今日盘前却大跌5.25%，引发市场关注。根据公司最新发布的财报，百济神州2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；其中产品收入79.85亿元，同比增长49.9%。然而，尽管财务表现显著改善，百济神州股价在盘前交易中却出现大幅下跌。市场分析人士指出，创新药板块近期持续调整，可能对百济神州股价造成压力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":0},{"id":"1161286799","title":"異動解讀 | 百濟神州股價盤前大跌5.25%，Q1財報虧損遠超預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1161286799","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161286799?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:48","pubTimestamp":1746622111,"startTime":"0","endTime":"0","summary":"5月7日盘前，生物科技公司百济神州股价大跌5.25%，引发市场关注。这一跌幅主要受到公司最新发布的2025年第一季度财报影响，财报显示公司仍未实现盈利，且亏损幅度超出市场预期。根据百济神州公布的2025年第一季度财报，公司实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%。值得注意的是，创新药概念股近期整体表现疲软。这一行业整体走势也在一定程度上影响了百济神州的股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 百济神州股价盘前大跌5.25%，Q1财报亏损远超预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":1},{"id":"2533809959","title":"百濟神州第一季度淨利虧損9450.3萬元，同比大幅減虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2533809959","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533809959?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:33","pubTimestamp":1746621226,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）5月7日晚间，百济神州（688235）发布2025年第一季度主要财务数据公告显示，报告期内，公司实现营业收入80.48亿元，同比增长50.2%；归属净利润为-9450.3万元，上年同期为-19.08亿元，同比大幅减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398350324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398350324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","06160","LU1969619763.USD","LU2328871848.SGD","ONC","BK1583","BK4139","BK1500","LU0588546209.SGD","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2533984281","title":"百濟神州(688235.SH)一季度營業總收入80.48億元，同比增長50.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984281","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984281?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:02","pubTimestamp":1746619377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(688235.SH)布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%:其中产品收入79.85亿元，同比增长49.9%。营业利润、利润总额由亏损转为盈利。产品收入的增长主要得益于公司自研产品百悦泽®(泽布替尼胶囊),以及百泽安®(替雷利珠单抗)和安进授权产品的销售增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1500","688235","06160","LU0588546209.SGD","ONC","BK4139","BK0239","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2533905984","title":"百濟神州首次實現季度GAAP盈利一季度澤布替尼全球銷售額超50億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533905984","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533905984?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:47","pubTimestamp":1746618420,"startTime":"0","endTime":"0","summary":"百济神州在2025年第一季度实现首次GAAP季度盈利，营收达80.48亿元，同比增长50.2%。核心产品泽布替尼全球销售额突破56.92亿元，其中在美国市场销售额达到40.41亿元，同比增长61.9%，并成为美国CLL和BTK抑制剂市场的领导者。公司预计全年营业收入将介于352亿元至381亿元之间，并重申经营利润为正且经营活动产生现金流为正。此外，百济神州在全球六大洲的业务布局进一步加强，展示了其在肿瘤创新领域的强劲增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719591394ef391b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719591394ef391b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2533264981","title":"百濟神州（06160）2025Q1強勁增長 首次實現季度GAAP盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533264981","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533264981?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:43","pubTimestamp":1746618233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年5月7日，百济神州发布2025年第一季度美股业绩报告及A股业绩快报。业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。财务表现方面，2025年第一季度，百济神州凭借全球收入的快速增长和经营费用的有效管理，在盈利方面再次取得重大进展。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。同时，百济神州预计将于2025年下半年完成BGB-58067和BG-89894联合治疗临床试验的首例患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1500","688235","06160","LU0588546209.SGD","ONC","BK4139","BK0239","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2533848699","title":"A股公告精選 | 百濟神州(688235.SH)第一季度營業利潤、利潤總額由虧轉盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533848699","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533848699?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:39","pubTimestamp":1746617962,"startTime":"0","endTime":"0","summary":"今日关注百济神州、源杰科技、纬德信息等公司公告。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0588546209.SGD","BK0239","LU0307460666.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1588","BK1500","688235","399300","BK4139","BK1583","159982","ONC","BK1161"],"gpt_icon":0},{"id":"2533098132","title":"百濟神州：第一季度淨虧損9450.3萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533098132","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533098132?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:23","pubTimestamp":1746616993,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州5月7日发布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%；归属于母公司所有者的净利润为-9450.3万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398303029.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398303029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","LU2328871848.SGD","ONC","06160","BK1588","BK1500","LU0588546209.SGD","BK1583","LU1969619763.USD","BK1161","BK4139"],"gpt_icon":0},{"id":"2533983707","title":"百濟神州Q1營收增長50.2%至80.48億元，百悅澤®全球銷售額總計56.92億","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983707","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533983707?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:05","pubTimestamp":1746615944,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布2025年一季报。披露公司Q1营收增长50.2%至80.48亿元，净亏损9450.3万元。2025年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%，在血液肿瘤领域进一步巩固领导地位。中国销售额总计5.90亿元，同比增长43.1%，主要得益于该产品在已获批适应症领域的销售增长。百悦泽临床开发项目迄今已在全球超过30个国家和地区开展超过35项试验，入组约7,100例患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-13","current":-64.235992,"percent":0.011364,"low":-64.911375,"twenty":-43.211621,"median":-38.58804,"eighty":-28.814932,"high":-22.805663,"avg":-37.142289,"sd":9.154987,"marketCap":25204019315},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-13","current":-64.235992,"twenty":-43.211621,"median":-38.58804,"eighty":-28.814932,"marketCap":25204019315}],"updateTime":1747247685495}}}